This study investigates pancreatic ductal adenocarcinoma (PDAC).
The purpose of this study is to evaluate the use of chromatin immunoprecipitation (ChIP), a method to study protein-DNA interactions, as a diagnostic and prognostic tool for pancreatic cancer.
- Who can participate: Adults aged 18 or older who have pancreatic cancer can participate. Children and individuals unable to consent are not eligible.
- Study details: The study evaluates the chromatin immunoprecipitation (ChIP) assay for its effectiveness in diagnosing pancreatic cancer. A placebo will not be used in this study.